Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
11
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax ↓ 69% unless the benefit outweighs the
300 mg QD Voriconazole AUCτ ↓ 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax ↓ 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUCτ ↓ 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax ↑ 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUCτ ↑ 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
Voriconazole Cmax ↑ 104% voriconazole.
Voriconazole AUCτ ↑ 87%
Rifampicin (600 mg QD) Voriconazole Cmax ↓ 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUCτ ↓ 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] voriconazole is contraindicated
is likely to significantly increase
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Co-administration of intravenous artesunate with strong inhibitors of UGT enzymes (e.g. axitinib,
vandetanib, imatinib, diclofenac) may increase plasma exposures to DHA. Co-administration should
be avoided if possible (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-08-21T10:45:00Z · SHA-256 6f269d91185e892a68bd1b38d7e3b0a6a8ee162530520ecf09345a1801fc0b3b · Passage 859b140b9739d5581ace013701507f7b2ad7293ccfee339fabfc5141f550550b · Zeichen 336–572 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.